A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Alnylam Pharmaceuticals
93 participants
Apr 27, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Eligibility
Inclusion Criteria4
- Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
- Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications
- Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
- Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks
Exclusion Criteria2
- Has known secondary hypertension or serum potassium more than 5 mmol/L
- Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ALN-AGT01 RVR will be administered subcutaneously (SC)
Placebo will be administered SC
Zilebesiran will be administered SC
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07553442